Prasugrel for Secondary Prevention of Thrombotic Stroke.
作者信息
Yagita Yoshiki
机构信息
Department of Stroke Medicine, Kawasaki Medical School.
出版信息
J Atheroscler Thromb. 2023 Mar 1;30(3):220-221. doi: 10.5551/jat.ED213. Epub 2022 Jul 29.
Abstract
摘要
相似文献
1
Prasugrel for Secondary Prevention of Thrombotic Stroke.
J Atheroscler Thromb. 2023 Mar 1;30(3):220-221. doi: 10.5551/jat.ED213. Epub 2022 Jul 29.
2
Impact of clopidogrel and potent P2Y 12 -inhibitors on mortality and stroke in patients with acute coronary syndrome or undergoing percutaneous coronary intervention: a systematic review and meta-analysis.
Thromb Haemost. 2013 Jan;109(1):93-101. doi: 10.1160/TH12-06-0377. Epub 2012 Nov 29.
3
Associations Between Chronic Kidney Disease and Outcomes With Use of Prasugrel Versus Clopidogrel in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: A Report From the PROMETHEUS Study.
JACC Cardiovasc Interv. 2017 Oct 23;10(20):2017-2025. doi: 10.1016/j.jcin.2017.02.047. Epub 2017 Aug 2.
4
Secondary prevention of acute coronary events with antiplatelet agents (SPACE-AA): One-year real-world effectiveness and safety cohort study in the French nationwide claims database.
Atherosclerosis. 2019 Feb;281:98-106. doi: 10.1016/j.atherosclerosis.2018.11.037. Epub 2018 Dec 7.
5
Real-world observations with prasugrel compared to clopidogrel in acute coronary syndrome patients treated with percutaneous coronary intervention in the United States.
Curr Med Res Opin. 2014 Nov;30(11):2207-16. doi: 10.1185/03007995.2014.941055. Epub 2014 Jul 18.
6
VERifyNow in DIabetes high-on-treatment platelet reactivity: a pharmacodynamic study on switching from clopidogrel to prasugrel.
Acta Cardiol. 2015 Dec;70(6):728-34. doi: 10.2143/AC.70.6.3120187.
7
Switching from Clopidogrel to Prasugrel in patients undergoing PCI: A meta-analytic overview.
Platelets. 2016;27(2):93-104. doi: 10.3109/09537104.2015.1042447. Epub 2015 May 13.
8
Reduction in recurrent cardiovascular events with prasugrel compared with clopidogrel in patients with acute coronary syndromes from the TRITON-TIMI 38 trial.
Eur Heart J. 2008 Oct;29(20):2473-9. doi: 10.1093/eurheartj/ehn362. Epub 2008 Aug 5.
9
Comparison of prasugrel and clopidogrel-treated patients with acute coronary syndrome undergoing percutaneous coronary intervention: A propensity score-matched analysis of the Acute Myocardial Infarction in Switzerland (AMIS)-Plus Registry.
Eur Heart J Acute Cardiovasc Care. 2016 Feb;5(1):13-22. doi: 10.1177/2048872614566946. Epub 2015 Jan 22.
10
Efficacy of ex vivo autologous and in vivo platelet transfusion in the reversal of P2Y12 inhibition by clopidogrel, prasugrel, and ticagrelor: the APTITUDE study.
Circ Cardiovasc Interv. 2015 Nov;8(11):e002786. doi: 10.1161/CIRCINTERVENTIONS.115.002786.
本文引用的文献
1
Efficacy and Safety of Prasugrel vs Clopidogrel in Thrombotic Stroke Patients With Risk Factors for Ischemic Stroke Recurrence: A Double-blind, Phase III Study (PRASTRO-III).
J Atheroscler Thromb. 2023 Mar 1;30(3):222-236. doi: 10.5551/jat.63473. Epub 2022 May 21.
2
Efficacy and Safety of Prasugrel by Stroke Subtype: A Sub-Analysis of the PRASTRO-I Randomized Controlled Trial.
J Atheroscler Thromb. 2021 Feb 1;28(2):169-180. doi: 10.5551/jat.56093. Epub 2020 Jun 4.
3
Safety and Efficacy of Prasugrel in Elderly/Low Body Weight Japanese Patients with Ischemic Stroke: Randomized PRASTRO-II.
Cerebrovasc Dis. 2020;49(2):152-159. doi: 10.1159/000506825. Epub 2020 Mar 24.
4
Comparison of prasugrel and clopidogrel in patients with non-cardioembolic ischaemic stroke: a phase 3, randomised, non-inferiority trial (PRASTRO-I).
Lancet Neurol. 2019 Mar;18(3):238-247. doi: 10.1016/S1474-4422(18)30449-6. Epub 2019 Feb 12.
5
Efficacy and safety of adjusted-dose prasugrel compared with clopidogrel in Japanese patients with acute coronary syndrome: the PRASFIT-ACS study.
Circ J. 2014;78(7):1684-92. doi: 10.1253/circj.cj-13-1482. Epub 2014 Apr 22.
6
Thienopyridine derivatives versus aspirin for preventing stroke and other serious vascular events in high vascular risk patients.
Cochrane Database Syst Rev. 2009 Oct 7;2009(4):CD001246. doi: 10.1002/14651858.CD001246.pub2.
7
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
N Engl J Med. 2007 Nov 15;357(20):2001-15. doi: 10.1056/NEJMoa0706482. Epub 2007 Nov 4.
8
Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects.
Blood. 2006 Oct 1;108(7):2244-7. doi: 10.1182/blood-2006-04-013052. Epub 2006 Jun 13.
9
Thienopyridines or aspirin to prevent stroke and other serious vascular events in patients at high risk of vascular disease? A systematic review of the evidence from randomized trials.
Stroke. 2000 Jul;31(7):1779-84. doi: 10.1161/01.str.31.7.1779.
Zotero 插件